VTL — Invictus Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- AU$3.60m
- AU$3.83m
- AU$0.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 51,428.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1403614.29% | ||
Financial Summary
| Year End 30th Jun | Unit | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.78 | 0.1 | 0.08 | n/a | 0 | n/a | n/a | -90.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invictus Therapeutics Ltd, formerly VGI Health Technology Limited, is an Australia-based biotechnology company. The Company is developing and commercializing prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential. This therapeutic potential includes Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (Pancreatic Cancer), hyperlipidaemia, hypertension and diabetes. The Company owns and controls patent and other intellectual property rights for novel approaches to noninvasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.
Directors
- Last Annual
- June 30th, 2019
- Last Interim
- December 31st, 2019
- Incorporated
- September 22nd, 2004
- Public Since
- May 28th, 2021
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- National Stock Exchange of Australia
- Shares in Issue
- 179,998,454
- Address
- Suite 4, 24 Birdwood Lane, Lane Cove, PERTH, 2066
- Web
- https://vgiht.com/
- Phone
- +61 282798908
- Auditors
- Hall Chadwick
Upcoming Events for VTL
Similar to VTL
GO-DX (Aust)
National Stock Exchange of Australia
IQX
National Stock Exchange of Australia
FAQ
What is the Invictus Therapeutics share price?
As of Today at 18:29 UTC, shares in Invictus Therapeutics are trading at AU$0.02. This share price information is delayed by 15 minutes.
How has the Invictus Therapeutics share price performed this year?
Shares in Invictus Therapeutics last closed at AU$0.02 and the price had moved by over the past 365 days. In terms of relative price strength the Invictus Therapeutics share price has underperformed the ASX All Ordinaries Index by -4.41% over the past year.
What are the analyst and broker recommendations for Invictus Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Invictus Therapeutics dividend yield?
Invictus Therapeutics does not currently pay a dividend.
Does Invictus Therapeutics pay a dividend?
Invictus Therapeutics does not currently pay a dividend.
When does Invictus Therapeutics next pay dividends?
Invictus Therapeutics does not currently pay a dividend.
How do I buy Invictus Therapeutics shares?
To buy shares in Invictus Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Invictus Therapeutics?
As of the previous close price of AU$0.02, shares in Invictus Therapeutics had a market capitalisation of AU$3.60m.
Where are Invictus Therapeutics shares listed?
Here are the trading details for Invictus Therapeutics:
- Country of listing: Australia
- Exchange: NSX
- Ticker Symbol: VTL
What kind of share is Invictus Therapeutics?
Based on an overall assessment of its quality, value and momentum Invictus Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Invictus Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Invictus Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Invictus Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -2.32%.
As of the last closing price of AU$0.02, shares in Invictus Therapeutics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Invictus Therapeutics PE Ratio?
The Invictus Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Invictus Therapeutics?
Invictus Therapeutics' management team is headed by:
- Louis Panaccio - NEC
- Gregory Starr - SEC
- Weidong Chen - NED
- Wei Jiang - NED
- Glenn Tong - NED
- Steven Yu - NED